723 related articles for article (PubMed ID: 21115743)
1. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
2. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.
Li H; Cai Q; Wu H; Vathipadiekal V; Dobbin ZC; Li T; Hua X; Landen CN; Birrer MJ; Sánchez-Beato M; Zhang R
Mol Cancer Res; 2012 Nov; 10(11):1462-72. PubMed ID: 22964433
[TBL] [Abstract][Full Text] [Related]
3. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.
Garipov A; Li H; Bitler BG; Thapa RJ; Balachandran S; Zhang R
Mol Cancer Res; 2013 Apr; 11(4):360-9. PubMed ID: 23360797
[TBL] [Abstract][Full Text] [Related]
4. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
6. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.
Li H; Bitler BG; Vathipadiekal V; Maradeo ME; Slifker M; Creasy CL; Tummino PJ; Cairns P; Birrer MJ; Zhang R
Cancer Prev Res (Phila); 2012 Mar; 5(3):484-91. PubMed ID: 22144423
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹).
Semaan A; Qazi AM; Seward S; Chamala S; Bryant CS; Kumar S; Morris R; Steffes CP; Bouwman DL; Munkarah AR; Weaver DW; Gruber SA; Batchu RB
Pharm Res; 2011 Dec; 28(12):3079-90. PubMed ID: 21818714
[TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
[TBL] [Abstract][Full Text] [Related]
9. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
Amatangelo MD; Garipov A; Li H; Conejo-Garcia JR; Speicher DW; Zhang R
Cell Cycle; 2013 Jul; 12(13):2113-9. PubMed ID: 23759589
[TBL] [Abstract][Full Text] [Related]
13. The role of EZH2 and DNA methylation in hMLH1 silencing in epithelial ovarian cancer.
Wang J; Yu L; Cai J; Jia J; Gao Y; Liang M; Wang Z
Biochem Biophys Res Commun; 2013 Apr; 433(4):470-6. PubMed ID: 23523787
[TBL] [Abstract][Full Text] [Related]
14. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
15. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells.
Wei Y; Chen YH; Li LY; Lang J; Yeh SP; Shi B; Yang CC; Yang JY; Lin CY; Lai CC; Hung MC
Nat Cell Biol; 2011 Jan; 13(1):87-94. PubMed ID: 21131960
[TBL] [Abstract][Full Text] [Related]
16. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
[TBL] [Abstract][Full Text] [Related]
17. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
18. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
19. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
20. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Li T; Cai J; Ding H; Xu L; Yang Q; Wang Z
Cancer Biol Ther; 2014 Mar; 15(3):271-8. PubMed ID: 24335192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
